Pharmafile
Is the Current EU Legal Framework for Orphan Medicines Fit for Purpose?
Autumn 2019
Maria Isabel Manley, partner and head of the UK Global Life Sciences Practice, and Chris Boyle, associate, at Sidley, discuss the impact of regulatory frameworks on medicines for rare diseases.
得意分野
Suggested News & Insights
Recharge & Recaffeinate With Sidley @ JPMMonday, January 11, 2027 – Tuesday, January 12, 2027GMP 2026: Regulatory Reliance, AI, and the Future of Pharmaceutical ManufacturingWednesday, December 2, 2026FDA Finalizes New Dietary Ingredient Guidance, but Questions RemainOctober 23, 2026FDA Announces Rare Disease Framework Initiative to Foster Consistent Review Approach Tailored to Unique Drug Development Considerations for Rare DiseasesOctober 20, 2026Sidley Represents Strategic Partnership Between Silgan and AIP in US$7.3 Billion Transaction to Create Diversified Global Metal Packaging BusinessOctober 19, 20262026 Momentum Food and Beverage ExchangeOctober 6-7, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory